Catalent Inc (CTLT)

[Trend-Setter]

Latest MACIVIVA update: Mymetics'(octqb:MYMX) virosomes delivered to Upperton.

"Received our latest delivery of #virosomes for the #MACIVIVA project. This project is funded by the #EU to improve the stability and shelf-life of vaccines #formulationdevelopment #vaccines #WednesdayMotivation"

Received our latest delivery of #virosomes for the #MACIVIVA project. This project is funded by the #EU to improve the stability and shelf-life of vaccines #formulationdevelopment #vaccines #WednesdayMotivation

— Upperton Pharma Solutions (@UppertonLtd) September 19, 2018

"Having sublingual, nasal and/or oral solid vaccine dosage forms suitable for storage under all world climates represent major innovations and will have important impacts for therapeutic and prophylactic vaccines. These non-invasive vaccine administration routes are expected to elicit the immune response in the relevant immune compartments (blood and/or mucosa) and may offer the major advantage of needle-free vaccination, a painless approach favoring a broader population acceptance. Eliminating syringes, needles and vials with diluents for vaccine reconstitution or adjuvant preparation would also lower the production costs, rendering vaccine handling safer with a simplified logistics."

https://cordis.europa.eu/result/rcn/194900_en.html

Ramping Up! final stage nears completion.